All-Oral AML Regimen Shows Promise for Older, Unfit Patients

(MedPage Today) -- An all-oral combination of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) was active and safe in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive chemotherapy, results of a phase...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news